BCIQ Profiles

Company Profile Report
1113 CYTK
BioCentury & Getty Images

Product Development

Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients

Nov 13, 2020 | 11:01 PM GMT

Updated data from the Phase III GALACTIC-HF study of omecamtiv mecarbil show it may be particularly useful in a more severe subgroup of heart failure patients.

The latest readout from Cytokinetics Inc.

Read the full 562 word article

How to gain access

Continue reading with a
two-week free trial.